Pipeline

Program Indication Research Preclinical Phase 1 Phase 2 Phase 3
Efzofitimod
(ATYR1923)
Pulmonary Sarcoidosis

 

Other ILDs (CTD-ILD; CHP)(1)

 

Healthy Japanese Volunteers(2)

 

ATYR2810 Solid Tumors

 

NRP2 mAbs Cancer; Inflammation

 

AARS-1; DARS‑1(3) Cancer; Fibrosis; Inflammation

 

Program Target Phase
Efzofitimod (ATYR1923) Pulmonary Sarcoidosis Phase 2
Other ILDs (CTD-ILD; CHP)1 Phase 1
Healthy Japanese Volunteers2 Phase 1
ATYR2810 Solid Tumors Preclinical
NRP2 mAbs Cancer; Inflammation Research
AARS-1; DARS-1(3) Cancer; Fibrosis; Inflammation Research

(1) CTD-ILD: connective tissue disease-related ILD (e.g. Scleroderma-related ILD); CHP: chronic hypersensitivity pneumonitis
(2) In partnership with Kyorin Pharmaceutical Co., Ltd. Kyorin’s Phase 1 study in healthy Japanese volunteers has been completed. Kyorin is eligible to participate in future efzofitimod trials sponsored by aTyr.
(3) The next two candidates from our tRNA synthetase platform; initial focus on NK cell biology.